For: | Leowattana W, Leowattana T. Potassium-competitive acid blockers and gastroesophageal reflux disease. World J Gastroenterol 2022; 28(28): 3608-3619 [PMID: PMC9372813 DOI: 10.3748/wjg.v28.i28.3608] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v28/i28/3608.htm |
Number | Citing Articles |
1 |
Georges Jourdi, Jean-Sébastien Hulot, Pascale Gaussem. An update on oral antiplatelet drug interactions with proton pump inhibitors: what are the risks?. Expert Opinion on Drug Metabolism & Toxicology 2024; 20(8): 749 doi: 10.1080/17425255.2024.2378888
|
2 |
Xinxu Zhou, Hui Duan, Qian Li, Qiong Wang, Xiaobin Sun. Efficacy and safety of potassium-competitive acid inhibitors in the treatment of gastroesophageal reflux: a systematic review and meta-analysis. Scandinavian Journal of Gastroenterology 2024; 59(7): 788 doi: 10.1080/00365521.2024.2349638
|
3 |
ChaoRong Bian, Ping Shen, YunPeng Zang, Wen Liu, Peng Zhou. Vonoprazan Fumarate: A Promising Therapeutic Option for the Rapid Relief of Laryngopharyngeal Reflux Disease. Journal of Voice 2025; doi: 10.1016/j.jvoice.2024.12.031
|
4 |
Piotr Kucharczyk, Karolina Anna Parzęcka, Michał Jakub Symulewicz, Weronika Zań, Kinga Szczepanik, Olaf Domaradzki, Bartłomiej Kusy, Mateusz Michalak, Marta Stolińska. Innovative therapeutic strategies in the treatment of gastroesophageal reflux disease (GERD): A review of progress and perspectives. Wiadomości Lekarskie 2024; 77(6): 1271 doi: 10.36740/WLek202406124
|
5 |
Mujtaba Alrayah, Rajab Alzahrani, Mohammed A Alghamdi, Kholoud M Alghamdi, Faisal F Almutairi, Anwar A Alghamdi, Raghad A Alzahrani, Taif A Bajaber, Tahani F Alanazi, Haya A Alnafisah. Assessment of the Current Knowledge and Practice of General Practitioners Towards Laryngopharyngeal Reflux in Saudi Arabia. Cureus 2023; doi: 10.7759/cureus.38043
|
6 |
M.A. Valdovinos Díaz, M. Amieva-Balmori, R. Carmona-Sánchez, E. Coss-Adame, O. Gómez-Escudero, M. González-Martínez, F. Huerta-Iga, E. Morel-Cerda, J.M. Remes-Troche, J.L. Tamayo-de la Cuesta, G. Torres-Villalobos, L.R. Valdovinos-García, G. Vázquez-Elizondo, A.S. Villar-Chávez, J.A. Arenas-Martínez. Good clinical practice recommendations for the diagnosis and treatment of gastroesophageal reflux disease. An expert review from the Asociación Mexicana de Gastroenterología. Revista de Gastroenterología de México (English Edition) 2024; 89(1): 121 doi: 10.1016/j.rgmxen.2023.12.002
|
7 |
阳 高. Advances in the Treatment of Gastroesophageal Reflux Disease. Advances in Clinical Medicine 2024; 14(05): 1790 doi: 10.12677/acm.2024.1451617
|
8 |
Angela Tietto, Sofia Faggin, Carmelo Scarpignato, Edoardo Vincenzo Savarino, Maria Cecilia Giron. Safety of potassium-competitive acid blockers in the treatment of gastroesophageal reflux disease. Expert Opinion on Drug Metabolism & Toxicology 2025; 21(1): 53 doi: 10.1080/17425255.2024.2397433
|
9 |
E. A. Ortenberg, M. V. Lyapina, E. F. Dorodnyeva. Competitive proton pump inhibitors - status and Prospects of use. Experimental and Clinical Gastroenterology 2023; (4): 86 doi: 10.31146/1682-8658-ecg-212-4-86-92
|
10 |
Jiten P. Kothadia, Colin W. Howden. Potassium-Competitive Acid Blockers for the Treatment of Gastroesophageal Reflux Disease. Foregut: The Journal of the American Foregut Society 2024; 4(1): 7 doi: 10.1177/26345161231181357
|
11 |
岚 卿. Progress of Potassium-Competitive Acid Blocker Tegoprazan in the Treatment of Acid-Related Diseases. Advances in Clinical Medicine 2024; 14(08): 117 doi: 10.12677/acm.2024.1482189
|
12 |
Eunsol Yang, Inyoung Hwang, Sang Chun Ji, John Kim, SeungHwan Lee. Population pharmacokinetic analysis of zastaprazan (JP‐1366), a novel potassium‐competitive acid blocker, in patients and healthy volunteers. CPT: Pharmacometrics & Systems Pharmacology 2024; 13(12): 2150 doi: 10.1002/psp4.13228
|
13 |
S. V. Tikhonov, E. N. Kareva, S. Yu. Serebrova, G. F. Vasilenko, M. K. Vasilyeva, S. A. Makhortova, N. V. Pavlova. New achievements of pharmacology for practical medicine in prevention and therapy of acid-dependent diseases. Meditsinskiy sovet = Medical Council 2023; (8): 33 doi: 10.21518/ms2023-133
|
14 |
Jeremy Klein, Robert T. Kavitt. Gastroesophageal Reflux Disease. 2023; : 61 doi: 10.1007/978-3-031-48241-0_8
|
15 |
Sergey M Kotelevets. Risks of anti-<i>Helicobacter</i> therapy and long-term therapy with antisecretory drugs. World Journal of Gastroenterology 2025; 31(4): 101933 doi: 10.3748/wjg.v31.i4.101933
|
16 |
M.A. Valdovinos-Diaz, M. Amieva-Balmori, R. Carmona-Sánchez, E. Coss-Adame, O. Gómez-Escudero, M. González-Martínez, F. Huerta-Iga, E. Morel-Cerda, J.M. Remes-Troche, J.L. Tamayo-de la Cuesta, G. Torres-Villalobos, L.R. Valdovinos-García, G. Vázquez-Elizondo, A.S. Villar-Chávez, J.S. Arenas-Martínez. Recomendaciones de buena práctica clínica en el diagnóstico y tratamiento de la enfermedad por reflujo gastroesofágico. Revisión por expertos de la Asociación Mexicana de Gastroenterología. Revista de Gastroenterología de México 2024; 89(1): 121 doi: 10.1016/j.rgmx.2023.12.002
|
17 |
Seo Yeon Kim, Jung-Ho Yoon, Da Hyun Jung, Ga Hee Kim, Chul Hoon Kim, Sang Kil Lee. Fexuprazan safeguards the esophagus from hydrochloric acid-induced damage by suppressing NLRP1/Caspase-1/GSDMD pyroptotic pathway. Frontiers in Immunology 2024; 15 doi: 10.3389/fimmu.2024.1410904
|
18 |
Shupeng Zou, Mengling Ouyang, Qian Cheng, Xuan Shi, Minghui Sun. Acid‐suppressive drugs: A systematic review and network meta‐analysis of their nocturnal acid‐inhibitory effect. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 2024; 44(2): 171 doi: 10.1002/phar.2899
|
19 |
Su Il Kim, Young Chan Lee, Wonjae Cha, Ah Ra Jung, Jeon Yeob Jang, Jeong-Seok Choi, Dong Kun Lee, Hwan Ho Lee, Min Su Kwon, Yoon Se Lee, Young-Gyu Eun. Efficacy and safety of fexuprazan in patients with symptoms and signs of laryngopharyngeal reflux disease: a randomized clinical trial. European Archives of Oto-Rhino-Laryngology 2024; 281(11): 5873 doi: 10.1007/s00405-024-08877-6
|